These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30024293)

  • 1. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
    Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
    Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Mechanisms in Myelodysplastic Syndrome.
    Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
    Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
    Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
    Nakajima H
    Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
    Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
    Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
    Sallman DA; Tanaka TN; List A; Bejar R
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunosuppressive drugs in myelodysplastic syndromes.
    Epling-Burnette PK; McDaniel J; Wei S; List AF
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):519-41. PubMed ID: 23163589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current perspective of low-grade myelodysplastic syndrome in children.
    Hasegawa D
    Int J Hematol; 2016 Apr; 103(4):360-4. PubMed ID: 26939774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
    Warlick ED; Miller JS
    Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
    Ivy KS; Brent Ferrell P
    Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
    Barrett AJ; Sloand EM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
    Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
    Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic aspects of hypoplastic myelodysplastic syndrome.
    Calado RT
    Semin Oncol; 2011 Oct; 38(5):667-72. PubMed ID: 21943673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the immune system in myelodysplasia: implications for therapy.
    Sloand EM; Rezvani K
    Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
    Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
    Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes.
    Greenberg PL; Young NS; Gattermann N
    Hematology Am Soc Hematol Educ Program; 2002; ():136-61. PubMed ID: 12446422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic immune response dysregulation in MDS pathogenesis.
    Barreyro L; Chlon TM; Starczynowski DT
    Blood; 2018 Oct; 132(15):1553-1560. PubMed ID: 30104218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.